LMB / Science / Research Leaders / Fellows / Paul Edelstein
Fellow

Paul Edelstein

Sponsored by Lalita Ramakrishnan

Paul Edelstein
Cell Biology

I am an infectious diseases clinician and clinical microbiologist at the University of Pennsylvania, as well as a long-time authority on Legionnaires’ disease. I have extensive experience in studying microbial pathogenesis, antimicrobial resistance and methods of studying antimicrobial activity in vitro and in vivo. I have been working with Lalita Ramakrishnan and her research group for close to three decades on innate immunity to tuberculosis and potential adjunctive therapies for tuberculosis. I look forward to working with others at the LMB who are studying infectious diseases.

Selected Publications

Rethinking the burden of latent tuberculosis to reprioritize research.Behr MA, Edelstein PH, Ramakrishnan LNat Microbiol 9(5): 1157-1158 (2024)
Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.Narayanan N, Mathers AJ, Wenzler E, Moore NM, Giske CG, Mendes RE, Edelstein PHClin Infect Dis 79(2): 516-523 (2024)
A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis.Padmapriyadarsini C, Szumowski JD, Akbar N, Shanmugasundaram P, Jain A, Bathragiri M, Pattnaik M, Turuk J, Karunaianantham R, Balakrishnan S, Pati S, Kumar AKH, Rathore MK, Raja J, Naidu KR, Horn J, Whitworth L, Sewell R, Ramakrishnan L, Swaminathan S, Edelstein PHClin Pharmacol Ther 115(2): 324-332 (2024)
The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance.Lake MA, Adams KN, Nie F, Fowler E, Verma AK, Dei S, Teodori E, Sherman DR, Edelstein PH, Spring DR, Troll M, Ramakrishnan LProc Natl Acad Sci U S A 120(7): e2215512120 (2023)
OrcID